

1 **S3 Table. Selectivity and potency of EP₂ receptor agonists.**

| Receptor / Readout | EP2 / cAMP | | EP4 / cAMP | | EP2 / β -arrestin | | EP4 / β -arrestin | |
|-----------------------|------------|----------|------------|----------|-------------------------|----------|-------------------------|----------|
| Name | EC50 [nM] | Emax (%) | EC50 [nM] | Emax (%) | EC50 [nM] | Emax (%) | EC50 [nM] | Emax (%) |
| Alprostadil | 0.04 | 100 | 10 | 110 | 520 | 104 | 9 | 110 |
| PGE2 | 0.04 | 100 | 3 | 110 | 110 | 103 | 4 | 107 |
| ONO-18 c | <0.01 | 98 | 5 | 64 | 52 | 160 | 5,000 | 26 |
| ONO-18 k | 0.03 | 99 | >10,000 | 24 | 110 | 32 | >10,000 | 15 |
| Evatanepag | 0.6 | 100 | >10,000 | 32 | 290 | 41 | >10,000 | 10 |

2 n.a.: not assessed.

3